<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111025">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01987765</url>
  </required_header>
  <id_info>
    <org_study_id>198027-A</org_study_id>
    <nct_id>NCT01987765</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and
      efficacy of Relestat Ophthalmic Solution 0.05% in patients with allergic conjunctivitis who
      are treated with Relestat as standard of care in clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Percentage of Patients Reporting Adverse Events</measure>
    <time_frame>Up to 10 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>An adverse event is any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Eye Symptoms Total Score on a 4-Point Scale</measure>
    <time_frame>Baseline, 2 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Itchiness, conjunctival hyperaemia (redness), lacrimation (tearing), and foreign body sensation were each evaluated on a 4-point scale ranging from 0 (best) to 3 (worst). The eye symptom total score is the sum of the individual symptom scores and ranges from 0 (best) to 12 (worst). A negative number change from baseline indicates an improvement.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">847</enrollment>
  <condition>Conjunctivitis, Allergic</condition>
  <arm_group>
    <arm_group_label>Relestat Ophthalmic Solution 0.05%</arm_group_label>
    <description>Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relestat Ophthalmic Solution 0.05%</intervention_name>
    <description>Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.</description>
    <arm_group_label>Relestat Ophthalmic Solution 0.05%</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Allergic Conjunctivitis treated with Relestat Ophthalmic Solution in
        clinical practice.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Allergic Conjunctivitis treated with Relestat Ophthalmic Solution in
             clinical practice.

        Exclusion Criteria:

          -  None.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Gangwon-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>November 13, 2013</firstreceived_date>
  <firstreceived_results_date>March 26, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Relestat Ophthalmic Solution 0.05%</title>
          <description>Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="847"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="745"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety Assessment Population which included all patients who completed the study, was used for the analysis of baseline characteristics.</population>
      <group_list>
        <group group_id="B1">
          <title>Relestat Ophthalmic Solution 0.05%</title>
          <description>Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="745"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;20 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="143"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>20 to 29 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="129"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>30 to 39 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="139"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>40 to 49 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="127"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>50 to 59 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="84"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>60 to 69 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="73"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>â‰¥70 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="487"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="258"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Reporting Adverse Events</title>
        <description>An adverse event is any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.</description>
        <time_frame>Up to 10 Months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Assessment Population: included all patients who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Relestat Ophthalmic Solution 0.05%</title>
            <description>Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="745"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients Reporting Adverse Events</title>
            <description>An adverse event is any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.</description>
            <units>Percentage of Patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Eye Symptoms Total Score on a 4-Point Scale</title>
        <description>Itchiness, conjunctival hyperaemia (redness), lacrimation (tearing), and foreign body sensation were each evaluated on a 4-point scale ranging from 0 (best) to 3 (worst). The eye symptom total score is the sum of the individual symptom scores and ranges from 0 (best) to 12 (worst). A negative number change from baseline indicates an improvement.</description>
        <time_frame>Baseline, 2 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy Assessment Population: included all patients in the Safety Assessment Population whose data was available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Relestat Ophthalmic Solution 0.05%</title>
            <description>Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="741"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Eye Symptoms Total Score on a 4-Point Scale</title>
            <description>Itchiness, conjunctival hyperaemia (redness), lacrimation (tearing), and foreign body sensation were each evaluated on a 4-point scale ranging from 0 (best) to 3 (worst). The eye symptom total score is the sum of the individual symptom scores and ranges from 0 (best) to 12 (worst). A negative number change from baseline indicates an improvement.</description>
            <units>Scores on a Scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.58" spread="2.25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at 2 Weeks</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.06" spread="2.17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 30 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President  GSE,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
